- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05114213
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC (MASPAC)
MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - a Randomized, Controlled Clinical Study
연구 개요
상세 설명
Patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy) will be included and randomized between arm A, receiving MR-guided adaptive SBRT of the primary tumor combined with continuation of SoC-CT, and arm B, continuing SoC-CT without SBRT.
Arm A: The primary tumor is treated with SBRT (6.6 Gy x 5) on a MR-LINAC in breath-hold technique. This scheme was shown to have a reasonable toxicity profile on a conventional LINAC. A low toxicity profile is even more important in patients with metastatic and therefore definitively incurable cancer. Therefore, treatment is performed on a MR-LINAC to deliver high doses to the tumor while keeping the toxicity profile as low as possible. For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney). Chemotherapy will be continued after SBRT. Arm B: Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Georg Beyer, Dr.
- 전화번호: +4989440072391
- 이메일: Georg.Beyer@med.uni-muenchen.de
연구 연락처 백업
- 이름: Ulrike Pflugradt
- 이메일: Ulrike.Pflugradt@med.uni-muenchen.de
연구 장소
-
-
-
Heidelberg, 독일
- 아직 모집하지 않음
- University Hospital of Heidelberg, Dep. of Radiation Oncology
-
연락하다:
- Juliane Hörner-Rieber, PD Dr.
-
-
Bavaria
-
Munich, Bavaria, 독일, 81377
- 모병
- University of Munich, Dep. of Radiation Oncology
-
수석 연구원:
- Maximilian Niyazi, MD, MSc
-
-
-
-
-
Zürich, 스위스
- 아직 모집하지 않음
- University Hospital of Zurich
-
연락하다:
- Matthias Guckenberger, Prof. Dr.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male and female patients with histologically proven, metastatic pancreatic adenocarcinoma of the pancreatic head or body amenable for MR-guided adaptive SBRT with at least stable disease after 8 weeks of standard of care doublet chemotherapy
- age >18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Ability to follow study instructions and likely to attend and complete all required visits
Exclusion Criteria:
- Subjects not able to give consent
- Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical study
- Simultaneous participation in another clinical study or participation in any clinical trial involving an investigational medicinal product or treatment within 30 days prior to beginning of this study
- Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the study results, or may interfere with the subject's participation in this study
- Women of child bearing potential or sexually active males not willing to use effective contraception while on treatment and 12 weeks after the end of treatment (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases
- Biopsy proven tumor invasion into the stomach and/or duodenum
- Medically uncontrolled pain
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Arm A: SBRT
mPDAC patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy).
The primary tumor is treated with SBRT (6.6Gy x 5) on a MR-LINAC in breath-hold technique.
For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney).
Chemotherapy will be continued after SBRT.
|
online adaptive MR-guided hypofractionated stereotactic radiotherapy
다른 이름들:
The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
|
활성 비교기: Arm B: SOC
Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
|
The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Mean cumulative pain index
기간: through study completion, at least 24 weeks or until death
|
Mean Cumulative pain index: AUC of pain scores rated every 4 weeks until death or end of study using numeric rating scale (NRS, 0= no pain, 10 = worst pain) divided by number of multiples of 4 weeks since randomization
|
through study completion, at least 24 weeks or until death
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Number of biliary complications
기간: through study completion, at least 24 weeks or until death
|
Biliary complications defined as cholangitis or post-hepatic cholestasis requiring drainage
|
through study completion, at least 24 weeks or until death
|
Malnutrition
기간: through study completion, at least 24 weeks or until death
|
Nutritional status measuring bioimpedance-derived phase angle (BIA) every 12 weeks
|
through study completion, at least 24 weeks or until death
|
Treatment toxicity
기간: through study completion, at least 24 weeks or until death
|
Treatment toxicity according to CTCAE v5.0
|
through study completion, at least 24 weeks or until death
|
Death from any cause
기간: through study completion
|
through study completion
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Maximilian Niyazi, Prof. Dr., Depatment of Radiation Oncology, University Hospital, LMU Munich
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
췌장암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
-
Jonsson Comprehensive Cancer Center종료됨생화학적으로 재발하는 전립선암 | 전이성 전립선암 | 뼈의 전이성 악성 신생물 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
SBRT에 대한 임상 시험
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology완전한
-
Soonchunhyang University HospitalSMG-SNU Boramae Medical Center아직 모집하지 않음신생물 | 속발성 악성 신생물
-
European Organisation for Research and Treatment...아직 모집하지 않음유방암 | 대장암 | NSCLC | 전립선암 | 올리고전이성 질환
-
Sidney Kimmel Comprehensive Cancer Center at Johns...모집하지 않고 적극적으로
-
Sidney Kimmel Comprehensive Cancer Center at Johns...완전한
-
Istituto Clinico Humanitas아직 모집하지 않음
-
Universitaire Ziekenhuizen KU Leuven모병
-
Centro Cardiologico MonzinoIstituto Europeo di Oncologia모병